<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Inhibikase Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/inhibikase-therapeutics-inc</link>
<description>Latest news and press releases for Inhibikase Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 07 Apr 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/inhibikase-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835833b78dffbe2df0fc99a.webp</url>
<title>Inhibikase Therapeutics Inc</title>
<link>https://6ix.com/company/inhibikase-therapeutics-inc</link>
</image>
<item>
<title>Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension</title>
<link>https://6ix.com/company/inhibikase-therapeutics-inc/news/inhibikase-therapeutics-announces-enrollment-of-first-patient-in-improve-pah-global-phase-3-study-of-ikt-001-in-the-treatment-of-pulmonary-arterial-hypertension</link>
<guid isPermaLink="true">https://6ix.com/company/inhibikase-therapeutics-inc/news/inhibikase-therapeutics-announces-enrollment-of-first-patient-in-improve-pah-global-phase-3-study-of-ikt-001-in-the-treatment-of-pulmonary-arterial-hypertension</guid>
<pubDate>Tue, 07 Apr 2026 12:00:00 GMT</pubDate>
<description>WILMINGTON, Del., April 07, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension (“PAH”), announced today that the first patient has been enrolled in the Company’s pivotal Phase 3 study IMPROVE-PAH (IKT-001 for Measuring Pulmonary Vascular Resistance and Outcome Variables in a Phase 3 Evaluation of PAH; NCT07365332). “Enrollment of the first patient in our I</description>
</item>
<item>
<title>Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/inhibikase-therapeutics-inc/news/inhibikase-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4</link>
<guid isPermaLink="true">https://6ix.com/company/inhibikase-therapeutics-inc/news/inhibikase-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4</guid>
<pubDate>Fri, 03 Apr 2026 18:01:00 GMT</pubDate>
<description>WILMINGTON, Del., April 03, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced that the Company granted non-qualified stock options to purchase up to an aggregate of 685,718 shares of the Company’s common stock to five newly-hired non-executive employees under the Company’s 2026 Inducement Equity Plan (the “Inducement Plan”), effective as of March 31, 2026 (the “Effective Date”). The inducement grants were previously approved by the</description>
</item>
<item>
<title>Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity</title>
<link>https://6ix.com/company/inhibikase-therapeutics-inc/news/inhibikase-therapeutics-announces-full-year-2025-financial-results-and-highlights-recent-activity</link>
<guid isPermaLink="true">https://6ix.com/company/inhibikase-therapeutics-inc/news/inhibikase-therapeutics-announces-full-year-2025-financial-results-and-highlights-recent-activity</guid>
<pubDate>Thu, 26 Mar 2026 20:01:00 GMT</pubDate>
<description>WILMINGTON, Del., March 26, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, Pulmonary Arterial Hypertension (“PAH”), today reported financial results for the year ended December 31, 2025 and highlighted recent developments. “The fourth quarter of 2025 was a transformational quarter for the Company as we transitioned to a global</description>
</item>
<item>
<title>Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants</title>
<link>https://6ix.com/company/inhibikase-therapeutics-inc/news/inhibikase-therapeutics-announces-pricing-100-025400783</link>
<guid isPermaLink="true">https://6ix.com/company/inhibikase-therapeutics-inc/news/inhibikase-therapeutics-announces-pricing-100-025400783</guid>
<pubDate>Fri, 21 Nov 2025 02:54:00 GMT</pubDate>
<description>WILMINGTON, Del., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of pulmonary arterial hypertension (“PAH”), today announced the pricing of its underwritten public offering of 46,091,739 shares of common stock and pre-funded warrants to purchase 22,873,779 shares of common stock. The shares of common stock are being sold at an offering price of $1.45 pe</description>
</item>
<item>
<title>Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants</title>
<link>https://6ix.com/company/inhibikase-therapeutics-inc/news/inhibikase-therapeutics-announces-proposed-public-211200448</link>
<guid isPermaLink="true">https://6ix.com/company/inhibikase-therapeutics-inc/news/inhibikase-therapeutics-announces-proposed-public-211200448</guid>
<pubDate>Thu, 20 Nov 2025 21:12:00 GMT</pubDate>
<description>BOSTON and ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of pulmonary arterial hypertension (“PAH”), today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, Inhib</description>
</item>
<item>
<title>Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension</title>
<link>https://6ix.com/company/inhibikase-therapeutics-inc/news/inhibikase-therapeutics-advancing-ikt-001-210100522</link>
<guid isPermaLink="true">https://6ix.com/company/inhibikase-therapeutics-inc/news/inhibikase-therapeutics-advancing-ikt-001-210100522</guid>
<pubDate>Thu, 20 Nov 2025 21:01:00 GMT</pubDate>
<description>Phase 3 Study initiating in First Quarter of 2026 Single Pivotal Study Accelerates Potential FDA Approval Timeline by Approximately 3 Years BOSTON and ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, Pulmonary Arterial Hypertension (“PAH”), today announced that it expects to advance IKT-001 to a global pivotal</description>
</item>
<item>
<title>Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity</title>
<link>https://6ix.com/company/inhibikase-therapeutics-inc/news/inhibikase-therapeutics-announces-third-quarter-210100494</link>
<guid isPermaLink="true">https://6ix.com/company/inhibikase-therapeutics-inc/news/inhibikase-therapeutics-announces-third-quarter-210100494</guid>
<pubDate>Fri, 14 Nov 2025 21:01:00 GMT</pubDate>
<description>BOSTON and ATLANTA, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, Pulmonary Arterial Hypertension (“PAH”), today reported financial results for the quarter ended September 30, 2025 and highlighted recent developments. “During our third quarter of 2025, we continued to position the Company to advance IKT-001 toward a</description>
</item>
<item>
<title>Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer</title>
<link>https://6ix.com/company/inhibikase-therapeutics-inc/news/inhibikase-therapeutics-strengthens-leadership-team-120000592</link>
<guid isPermaLink="true">https://6ix.com/company/inhibikase-therapeutics-inc/news/inhibikase-therapeutics-strengthens-leadership-team-120000592</guid>
<pubDate>Tue, 19 Aug 2025 12:00:00 GMT</pubDate>
<description>BOSTON and ATLANTA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of pulmonary arterial hypertension (“PAH”), today announced the appointment of veteran biopharma executive Timothy Pigot as the Company’s Chief Commercial and Strategy Officer. “Tim Pigot is an accomplished pharma industry business leader and a deeply respected expert in the PAH market l</description>
</item>
<item>
<title>Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity</title>
<link>https://6ix.com/company/inhibikase-therapeutics-inc/news/inhibikase-therapeutics-announces-second-quarter-205000834</link>
<guid isPermaLink="true">https://6ix.com/company/inhibikase-therapeutics-inc/news/inhibikase-therapeutics-announces-second-quarter-205000834</guid>
<pubDate>Thu, 14 Aug 2025 20:50:00 GMT</pubDate>
<description>BOSTON and ATLANTA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, Pulmonary Arterial Hypertension (“PAH”), today reported financial results for the quarter ended June 30, 2025 and highlighted recent developments. “During our second quarter of 2025, we continued to position the Company to advance IKT-001 toward a late</description>
</item>
<item>
<title>Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity</title>
<link>https://6ix.com/company/inhibikase-therapeutics-inc/news/inhibikase-therapeutics-announces-first-quarter-200500496</link>
<guid isPermaLink="true">https://6ix.com/company/inhibikase-therapeutics-inc/news/inhibikase-therapeutics-announces-first-quarter-200500496</guid>
<pubDate>Wed, 14 May 2025 20:05:00 GMT</pubDate>
<description>Advancing IKT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial HypertensionBOSTON and ATLANTA, May 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial hypertension (“PAH”), today reported financial results for the quarter ended March 31, 2025 and highlighted recent developments. “During our first quarter of</description>
</item>
<item>
<title>Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer</title>
<link>https://6ix.com/company/inhibikase-therapeutics-inc/news/inhibikase-therapeutics-announces-appointment-david-120000968</link>
<guid isPermaLink="true">https://6ix.com/company/inhibikase-therapeutics-inc/news/inhibikase-therapeutics-announces-appointment-david-120000968</guid>
<pubDate>Mon, 14 Apr 2025 12:00:00 GMT</pubDate>
<description>BOSTON and ATLANTA, April 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial hypertension (“PAH”), today announced the appointment of David McIntyre as Chief Financial Officer, effective April 14, 2025. “David has extensive experience in financial strategy and corporate governance, as well as an established reputation withi</description>
</item>
<item>
<title>Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity</title>
<link>https://6ix.com/company/inhibikase-therapeutics-inc/news/inhibikase-therapeutics-announces-2024-financial-200100814</link>
<guid isPermaLink="true">https://6ix.com/company/inhibikase-therapeutics-inc/news/inhibikase-therapeutics-announces-2024-financial-200100814</guid>
<pubDate>Thu, 27 Mar 2025 20:01:00 GMT</pubDate>
<description>New Leadership and Focus on Advancement of IkT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial HypertensionBOSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial hypertension (“PAH”), today reported financial results for the year ended December 31, 2024 and highlighted recent developments. “The</description>
</item>
<item>
<title>Inhibikase Announces Expansion of Senior Leadership Team</title>
<link>https://6ix.com/company/inhibikase-therapeutics-inc/news/inhibikase-announces-expansion-senior-leadership-130000903</link>
<guid isPermaLink="true">https://6ix.com/company/inhibikase-therapeutics-inc/news/inhibikase-announces-expansion-senior-leadership-130000903</guid>
<pubDate>Mon, 24 Feb 2025 13:00:00 GMT</pubDate>
<description>--- Chris Cabell, MD MHS FACC Appointed President and Head of Research & Development --- --- John Adams, PhD Appointed Chief Scientific Officer --- --- Vince Aurentz to join Inhibikase Board of Directors --- BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced the appointment of two pharma industry executives with deep experience in pulmonary arterial hypertension (“PAH”) to its senior leadership team. Chris Cabell, M.</description>
</item>
<item>
<title>Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s Growth</title>
<link>https://6ix.com/company/inhibikase-therapeutics-inc/news/inhibikase-appoints-industry-veteran-mark-130000521</link>
<guid isPermaLink="true">https://6ix.com/company/inhibikase-therapeutics-inc/news/inhibikase-appoints-industry-veteran-mark-130000521</guid>
<pubDate>Tue, 18 Feb 2025 13:00:00 GMT</pubDate>
<description>-- Mr. Iwicki Brings Track Record of Operational Excellence and Significant Expertise in PAH and Cardiovascular Diseases -- -- Amit Munshi Appointed Chair of the Board of Directors -- BOSTON, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced the appointment of Mark Iwicki as the Company's Chief Executive Officer, replacing Dr. Milton H. Werner, founder of Inhibikase, effective February 14, 2025. Additionally, effective Febr</description>
</item>
</channel>
</rss>